Unknown PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT04265963

CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid Leukemia

Sponsor: Chongqing Precision Biotech Co., Ltd

Conditions Leukemia Leukemia, Myeloid Leukemia, Myeloid, Acute

Updated 8 times since 2020 Last updated: Apr 16, 2023 Started: Sep 1, 2019 Primary completion: Dec 31, 2023 Completion: Jul 1, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04265963, this PHASE1/PHASE2 trial focuses on Leukemia and Leukemia, Myeloid and remains ongoing. Sponsored by Chongqing Precision Biotech Co., Ltd, it has been updated 8 times since 2019, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

8 versions recorded

Apr 2025 — Present [monthly]

Unknown PHASE1/PHASE2

Status: Recruiting → Unknown
Sep 2024 — Apr 2025 [monthly]

Recruiting PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
May 2023 — Jul 2024 [monthly]

Recruiting PHASE1_PHASE2

Status: Unknown Status → Recruiting
Apr 2023 — May 2023 [monthly]

Unknown Status PHASE1_PHASE2

Status: Recruiting → Unknown Status

▶ Show 3 earlier versions

Apr 2021 — Apr 2023 [monthly]

Recruiting PHASE1_PHASE2
Jan 2021 — Apr 2021 [monthly]

Recruiting PHASE1_PHASE2
Mar 2020 — Jan 2021 [monthly]

Recruiting PHASE1_PHASE2

First recorded

Sep 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chongqing Precision Biotech Co., Ltd

Data source: Chongqing Precision Biotech Co., Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Kunming, China